Related Experiment Video
Updated: May 13, 2026
09:09
In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
Centers for cardiovascular outcomes research: defining a collaborative vision
Nakela L Cook1, Denise E Bonds, Catarina I Kiefe
1National Heart, Lung, and Blood Institute, 31 Center Drive, Bethesda, MD 20814, USA. nakela.cook@nih.gov
Circulation. Cardiovascular Quality and Outcomes
|March 14, 2013
Summary
The National Heart, Lung, and Blood Institute
Area of Science:
- Cardiovascular Outcomes Research
- Translational Science
- Healthcare Delivery Science
Background:
- Established the Centers for Cardiovascular Outcomes Research program in 2010.
- Recognizes the value of outcomes research in bridging translational gaps and informing clinical practice.
- Aims to generate new hypotheses for treatment and care.
Purpose of the Study:
- To understand and bridge translational gaps in cardiovascular medicine.
- To establish evidence for clinical practice and healthcare delivery.
- To generate new hypotheses for ongoing treatment and care questions.
Main Methods:
- Funded 3 independent centers and a research coordinating unit.
- Projects focus on care transitions, clinical events, quality of life, and patient outcomes.
- Examined healthcare reform impacts on cardiovascular care and outcomes.
Main Results:
- Characterized care transitions and predicted clinical events post-acute coronary syndrome.
- Identified factors associated with improved patient outcomes across cardiovascular conditions.
- Assessed the impact of healthcare reform on cardiovascular care and venous thromboembolism outcomes.
Conclusions:
- The program represents a significant investment in cardiovascular outcomes research.
- Leverages scientific rigor and collaboration to advance healthcare delivery science.
- Aims to achieve advancements beyond individual unit capabilities.
Related Concept Videos
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:26Coronary Artery Disease IV: Preventive Measures
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:28Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...